U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Surveillance: Post Drug-Approval Activities
  5. Questions and Answers on FDA's Adverse Event Reporting System (FAERS)
  6. Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between July - September 2014
  1. Questions and Answers on FDA's Adverse Event Reporting System (FAERS)

Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between July - September 2014


Product Name: Active Ingredient (Trade) or Product Class		 Potential Signal of a Serious Risk / New Safety Information Additional Information
(as of October 1, 2014)
Xenazine (Tetrabenazine) Death FDA decided that no action is necessary at this time based on available information.
Regadenoson (Lexiscan) Seizures, worsening or recurrence of seizures after use of aminophylline, cerebrovascular accident, and atrial fibrillation/atrial flutter The Warnings and Precautions section of the labeling for Lexiscan was updated in September 2014 to include:
  • seizure
  • warning not to use aminophylline in patients who have seizures after receiving regadenoson
  • cerebrovascular accident
  • atrial fibrillation/atrial flutter
 
Back to Top